Association of glucagon-like peptide-1 system with the prevention and treatment of nonalcoholic fatty liver disease

Hongliang CUI; Li XU; Tong LU

doi:10.3969/j.issn.1001-5256.2022.06.039

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(6): 1406-1410

PDF( 2126 KB)

Association of glucagon-like peptide-1 system with the prevention and treatment of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.06.039

Hongliang CUI^a,
Li XU^{b
,
,
,},
Tong LU^a

a.
College of Medical Technology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China
b.
Medical Experimental Research Center, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China

Research funding:

National College Students' Innovation and Entrepreneurship Training Program (S202010716012);

Scientific Research Plan Projects of Education Department of Shaanxi Province (19JK0243)

More Information

Corresponding author: XU Li, maolixu@163.com (ORCID: 0000-0002-6755-9445)
Received Date: 2021-10-15
Accepted Date: 2021-11-16
Published Date: 2022-06-20

Abstract

Abstract

With a large number of patients, nonalcoholic fatty liver disease (NAFLD) has become one of the major chronic liver diseases that jeopardize the health of people worldwide. This article introduces the major factors in glucagon-like peptide-1 (GLP-1) system that are associated with the production, decomposition, and receptor effect of GLP-1, summarizes the regulatory mechanism of GLP-1 system on NAFLD, and proposes the main problems of GLP-1 system in the treatment of NAFLD, so as to provide a reference for the research and clinical treatment of NAFLD.
- Glucagon-Like Peptide 1,
- Non-alcoholic Fatty Liver Disease,
- Lipid Metabolism

FullText(HTML)

References(52)

References

[1]	NAKATSUKA T, TATEISHI R, KOIKE K. Changing clinical management of NAFLD in Asia[J]. Liver Int, 2021. DOI: 10.1111/liv.15046.[Online ahead of print]
[2]	ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[3]	BESSONE F, RAZORI MV, ROMA MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76(1): 99-128. DOI: 10.1007/s00018-018-2947-0.
[4]	EL-AGROUDY NN, KURZBACH A, RODIONOV RN, et al. Are lifestyle therapies effective for NAFLD treatment?[J]. Trends Endocrinol Metab, 2019, 30(10): 701-709. DOI: 10.1016/j.tem.2019.07.013.
[5]	ARMSTRONG MJ, HULL D, GUO K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis[J]. J Hepatol, 2016, 64(2): 399-408. DOI: 10.1016/j.jhep.2015.08.038.
[6]	ANDERSEN A, LUND A, KNOP FK, et al. Glucagon-like peptide 1 in health and disease[J]. Nat Rev Endocrinol, 2018, 14(7): 390-403. DOI: 10.1038/s41574-018-0016-2.
[7]	FUJIWARA Y, EGUCHI S, MURAYAMA H, et al. Relationship between diet/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes[J]. Endocrinol Diabetes Metab, 2019, 2(3): e00068. DOI: 10.1002/edm2.68.
[8]	SMITH NK, HACKETT TA, GALLI A, et al. GLP-1: Molecular mechanisms and outcomes of a complex signaling system[J]. Neurochem Int, 2019, 128: 94-105. DOI: 10.1016/j.neuint.2019.04.010.
[9]	DEACON CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes[J]. Front Endocrinol (Lausanne), 2019, 10: 80. DOI: 10.3389/fendo.2019.00080.
[10]	KAMAKURA R, RAZA GS, PRASANNAN A, et al. Dipeptidyl peptidase-4 and GLP-1 interplay in STC-1 and GLUTag cell lines[J]. Peptides, 2020, 134: 170419. DOI: 10.1016/j.peptides.2020.170419.
[11]	VARIN EM, MULVIHILL EE, BAGGIO LL, et al. Distinct neural sites of GLP-1R expression mediate physiological versus pharmacological control of incretin action[J]. Cell Rep, 2019, 27(11): 3371-3384.e3. DOI: 10.1016/j.celrep.2019.05.055.
[12]	MA H, HUANG W, WANG X, et al. Structural insights into the activation of GLP-1R by a small molecule agonist[J]. Cell Res, 2020, 30(12): 1140-1142. DOI: 10.1038/s41422-020-0384-8.
[13]	MVLLER TD, FINAN B, BLOOM SR, et al. Glucagon-like peptide 1 (GLP-1)[J]. Mol Metab, 2019, 30: 72-130. DOI: 10.1016/j.molmet.2019.09.010.
[14]	LI S, WANG X, ZHANG J, et al. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease[J]. Braz J Med Biol Res, 2018, 51(8): e7299. DOI: 10.1590/1414-431x20187299.
[15]	LEE J, HONG SW, RHEE EJ, et al. GLP-1 receptor agonist and non-alcoholic fatty liver disease[J]. Diabetes Metab J, 2012, 36(4): 262-267. DOI: 10.4093/dmj.2012.36.4.262.
[16]	YU X, HAO M, LIU Y, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy[J]. Eur J Pharmacol, 2019, 864: 172715. DOI: 10.1016/j.ejphar.2019.172715.
[17]	GILBERT MP, PRATLEY RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials[J]. Front Endocrinol (Lausanne), 2020, 11: 178. DOI: 10.3389/fendo.2020.00178.
[18]	TOBITA H, YAZAKI T, KATAOKA M, et al. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study[J]. J Clin Biochem Nutr, 2021, 68(2): 173-180. DOI: 10.3164/jcbn.20-129.
[19]	SHIRAKAWA J, FUJII H, OHNUMA K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice[J]. Diabetes, 2011, 60(4): 1246-1257. DOI: 10.2337/db10-1338.
[20]	SHEN T, XU B, LEI T, et al. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway[J]. Exp Ther Med, 2018, 16(4): 3121-3128. DOI: 10.3892/etm.2018.6554.
[21]	SANTOS FO, CORREIA B, MARINHO TS, et al. Anti-steatotic linagliptin pleiotropic effects encompasses suppression of de novo lipogenesis and ER stress in high-fat-fed mice[J]. Mol Cell Endocrinol, 2020, 509: 110804. DOI: 10.1016/j.mce.2020.110804.
[22]	OKUYAMA T, SHIRAKAWA J, TAJIMA K, et al. Linagliptin ameliorates hepatic steatosis via non-canonical mechanisms in mice treated with a dual inhibitor of insulin receptor and IGF-1 receptor[J]. Int J Mol Sci, 2020, 21(21): 7815. DOI: 10.3390/ijms21217815.
[23]	KAWAGUCHI T, NAKANO D, KOGA H, et al. Effects of a DPP4 inhibitor on progression of NASH-related HCC and the p62/ Keap1/Nrf2-pentose phosphate pathway in a mouse model[J]. Liver Cancer, 2019, 8(5): 359-372. DOI: 10.1159/000491763.
[24]	RANJBAR G, MIKHAILIDIS DP, SAHEBKAR A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box![J]. Metabolism, 2019, 101: 154001. DOI: 10.1016/j.metabol.2019.154001.
[25]	LEE M, SHIN E, BAE J, et al. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression[J]. Sci Rep, 2020, 10(1): 19429. DOI: 10.1038/s41598-020-75288-y.
[26]	ZHENG W, ZHOU J, SONG S, et al. Dipeptidyl-peptidase 4 inhibitor sitagliptin ameliorates hepatic insulin resistance by modulating inflammation and autophagy in ob/ob mice[J]. Int J Endocrinol, 2018, 2018: 8309723. DOI: 10.1155/2018/8309723.
[27]	WU C, CHEN W, DING H, et al. Salvianolic acid B exerts anti-liver fibrosis effects via inhibition of MAPK-mediated phospho-Smad2/3 at linker regions in vivo and in vitro[J]. Life Sci, 2019, 239: 116881. DOI: 10.1016/j.lfs.2019.116881.
[28]	KHALIL R, SHATA A, ABD EL-KADER EM, et al. Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling[J]. Toxicol Appl Pharmacol, 2020, 407: 115246. DOI: 10.1016/j.taap.2020.115246.
[29]	PATEL CHAVEZ C, CUSI K, KADIYALA S. The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD[J]. J Clin Endocrinol Metab, 2022, 107(1): 29-38. DOI: 10.1210/clinem/dgab578.
[30]	JIANPING W, XUELIAN Z, ANJIANG W, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of metabolic associated fatty liver disease: A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2021, 55(7): 586-593. DOI: 10.1097/MCG.0000000000001556.
[31]	LV X, DONG Y, HU L, et al. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review[J]. Endocrinol Diabetes Metab, 2020, 3(3): e00163. DOI: 10.1002/edm2.163.
[32]	WANG XC, GUSDON AM, LIU H, et al. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation[J]. World J Gastroenterol, 2014, 20(40): 14821-14830. DOI: 10.3748/wjg.v20.i40.14821.
[33]	VENDRELL J, EL BEKAY R, PERAL B, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance[J]. Endocrinology, 2011, 152(11): 4072-4079. DOI: 10.1210/en.2011-1070.
[34]	FANG QH, SHEN QL, LI JJ, et al. Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention[J]. Hepatol Res, 2019, 49(7): 743-757. DOI: 10.1111/hepr.13330.
[35]	FANG Y, JI L, ZHU C, et al. Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway[J]. Front Cell Dev Biol, 2020, 8: 602574. DOI: 10.3389/fcell.2020.602574.
[36]	YANG M, MA X, XUAN X, et al. Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system[J]. Front Pharmacol, 2020, 11: 432. DOI: 10.3389/fphar.2020.00432.
[37]	KUCHAY MS, KRISHAN S, MISHRA SK, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)[J]. Diabetologia, 2020, 63(11): 2434-2445. DOI: 10.1007/s00125-020-05265-7.
[38]	FENG WH, BI Y, LI P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial[J]. J Diabetes Investig, 2019, 10(2): 399-407. DOI: 10.1111/jdi.12888.
[39]	CHRISTOU GA, KATSIKI N, BLUNDELL J, et al. Semaglutide as a promising antiobesity drug[J]. Obes Rev, 2019, 20(6): 805-815. DOI: 10.1111/obr.12839.
[40]	NEWSOME P, FRANCQUE S, HARRISON S, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity[J]. Aliment Pharmacol Ther, 2019, 50(2): 193-203. DOI: 10.1111/apt.15316.
[41]	SAAD ZA, KHODEER DM, ZAITONE SA, et al. Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin[J]. Life Sci, 2020, 253: 117725. DOI: 10.1016/j.lfs.2020.117725.
[42]	LUO Y, YANG P, LI Z, et al. Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways[J]. Drug Des Devel Ther, 2019, 13: 4065-4074. DOI: 10.2147/DDDT.S224688.
[43]	SHAO N, YU XY, MA XF, et al. Exenatide delays the progression of nonalcoholic fatty liver disease in C57BL/6 mice, which may involve inhibition of the NLRP3 inflammasome through the mitophagy pathway[J]. Gastroenterol Res Pract, 2018, 2018: 1864307. DOI: 10.1155/2018/1864307.
[44]	TESHOME G, AMBACHEW S, FASIL A, et al. Efficacy of glucagon-like peptide-1 analogs in nonalcoholic fatty liver disease: A systematic review[J]. Hepat Med, 2020, 12: 139-151. DOI: 10.2147/HMER.S265631.
[45]	WU L, LIU Y, SHI L, et al. Promotion of apoptosis in high glucose-activated hepatic stellate cells by GLP-1 receptor agonist and its potential mechanism[J]. Gene Mol Res, 2017, 16(4): gmr16039818. DOI: 10.4238/gmr16039818.
[46]	HAN X, DING C, ZHANG G, et al. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway[J]. Biochem Biophys Res Commun, 2020, 525(4): 895-901. DOI: 10.1016/j.bbrc.2020.03.032.
[47]	GHADIEH HE, MUTURI HT, NAJJAR SM. Exenatide prevents diet-induced hepatocellular injury in a CEACAM1-dependent mechanism[J]. J Diabetes Treat, 2017, 2017(4): 10.29011/2574.7568.000033. DOI: 10.29011/2574.7568.000033.
[48]	REED J, KANAMARLAPUDI V. GLP-1. [M]//CHOI S. Encyclopedia of Signaling Molecules. Cham; Springer International Publishing. 2018: 2098-2106.
[49]	DHIR G, CUSI K. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: A novel therapeutic option[J]. J Investig Med, 2018, 66(1): 7-10. DOI: 10.1136/jim-2017-000554.
[50]	RICHARDS P, PARKER HE, ADRIAENSSENS AE, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model[J]. Diabetes, 2014, 63(4): 1224-1233. DOI: 10.2337/db13-1440.
[51]	CANTINI G, MANNUCCI E, LUCONI M. Perspectives in GLP-1 research: New targets, new receptors[J]. Trends Endocrinol Metab, 2016, 27(6): 427-438. DOI: 10.1016/j.tem.2016.03.017.
[52]	SOFOGIANNI A, FILIPPIDIS A, CHRYSAVGIS L, et al. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update[J]. World J Hepatol, 2020, 12(8): 493-505. DOI: 10.4254/wjh.v12.i8.493.

Relative Articles

[1]	Shukun YAO, Jing LIU, Tianhui ZHOU. Research advances in the pathogenesis of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(10): 1954-1958. doi: 10.12449/JCH241005
[2]	Chenlu ZHAO, Dongfang SHANG, Cheng ZHOU, Junhao SHI, Wenxia ZHAO. Mechanism of lipid metabolism mediated by hepatokines and adipokines in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 168-174. doi: 10.3969/j.issn.1001-5256.2023.01.026
[3]	Xiaodong ZHOU, Na TIAN, Minghua ZHENG. Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2336-2339. doi: 10.3969/j.issn.1001-5256.2023.10.010
[4]	Xiaoxia XUN, Cheng ZHOU, Wenxia ZHAO. Role of glucose and lipid metabolism mediated by the bile acid receptor Takeda G protein-coupled receptor 5 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 162-167. doi: 10.3969/j.issn.1001-5256.2023.01.025
[5]	Shuang ZHANG, Xiaohui LIU, Gang WANG, Li ZHANG, Yunjie ZHU, Jian WU, Yali LIU, Jing ZHANG. Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population[J]. Journal of Clinical Hepatology, 2022, 38(3): 547-552. doi: 10.3969/j.issn.1001-5256.2022.03.011
[6]	Yitong BAI, Lianjie LIN, Dongmei PEI. Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(4): 805-809. doi: 10.3969/j.issn.1001-5256.2022.04.013
[7]	Dongna ZHAO, Qian LIU, Huijie LIANG, Haozhe CUI, Lingqun MENG, Huiliang E, Liying CAO. Effect of ideal cardiovascular health metrics on the incidence rate of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 124-128. doi: 10.3969/j.issn.1001-5256.2022.01.019
[8]	Qian WANG, Chenrui ZHANG, Yingmei TANG. Research advances in glucose and lipid metabolism disorders in different types of chronic liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(8): 1937-1940. doi: 10.3969/j.issn.1001-5256.2022.08.043
[9]	Yuting LUAN, Zhongming HUANG, Wenjuan SHEN, Minghao HA, Zhibing XU. Research advances in metabolomics in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 943-946. doi: 10.3969/j.issn.1001-5256.2021.04.047
[10]	Meiying LI, Wanli JI, Wangzhenzu LIU, Tao WANG, Shengnan DU, Jingjing GAO, Yuanye JIANG, Cheng HU. A serum metabolomics study on the intervention of nonalcoholic fatty liver disease by equicaloric low-carbohydrate high-protein diet combined with aerobic exercise[J]. Journal of Clinical Hepatology, 2021, 37(11): 2605-2610. doi: 10.3969/j.issn.1001-5256.2021.11.023
[11]	Weichun XIAO, Wei AN. Role of mitochondrial injury in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1515-1521. doi: 10.3969/j.issn.1001-5256.2021.07.005
[12]	Peiyu ZHENG, Xiuqin AN, Jinchun LIU. Role of angiopoietin-like proteins in the development of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2680-2683. doi: 10.3969/j.issn.1001-5256.2021.11.042
[13]	Xiaohan YU, Yulu WANG, Xiaoyang XU, Jian PING, Changqing ZHAO. Effect of glucagon-like peptide-1 receptor agonist in treatment of nonalcoholic fatty liver disease and related mechanism[J]. Journal of Clinical Hepatology, 2021, 37(1): 196-199. doi: 10.3969/j.issn.1001-5256.2021.01.043
[14]	FENG Gong, YAN QinQin, HE Na, MI Man. From nonalcoholic fatty liver disease to metabolic fatty liver disease:An analysis based on disease heterogeneity[J]. Journal of Clinical Hepatology, 2020, 36(11): 2597-2600. doi: 10.3969/j.issn.1001-5256.2020.11.045
[15]	Gao JingJing, Wang Tao, Jiang YuanYe, Cao Qin. Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(8): 1880-1882. doi: 10.3969/j.issn.1001-5256.2020.08.044
[16]	WANG Xin, HU YiYang, LIU Ping, FENG Qin. Association between hypertension and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2584-2588. doi: 10.3969/j.issn.1001-5256.2020.11.042
[17]	Liu ZhiPing, Zhao ZhiWei, Zhang JinHua. Correlation of intestinal flora with serum glucagon-like peptide-1 level in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 136-139. doi: 10.3969/j.issn.1001-5256.2020.01.030
[18]	Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010
[19]	Yan Rong, Niu ChunYan, Yu Lu, Tian Yu. Interaction between autophagy and lipid metabolism in cell models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(10): 1981-1986. doi: 10.3969/j.issn.1001-5256.2017.10.027

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	李静静，赵渊宇，傅宏，滕飞，毛家玺，郭闻渊. 全胰切除联合自体胰岛细胞移植的研究进展. 临床肝胆病杂志. 2023(10): 2506-2512 . 本站查看
2.	李玲玲，张洋洋，白佳，杨虹，杨莹，吕海宏. 不同胰高血糖素样肽-1受体激动剂对骨代谢影响的研究进展. 中国临床药理学与治疗学. 2022(11): 1315-1320 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (659) PDF downloads(41)

Association of glucagon-like peptide-1 system with the prevention and treatment of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.06.039